176 related articles for article (PubMed ID: 14657601)
1. Forced expression of cytidine deaminase confers sensitivity to capecitabine.
Morita T; Matsuzaki A; Kurokawa S; Tokue A
Oncology; 2003; 65(3):267-74. PubMed ID: 14657601
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of sensitivity to capecitabine in human renal carcinoma cells transfected with thymidine phosphorylase cDNA.
Morita T; Matsuzaki A; Tokue A
Int J Cancer; 2001 May; 92(3):451-6. PubMed ID: 11291085
[TBL] [Abstract][Full Text] [Related]
3. Predictive markers of capecitabine sensitivity identified from the expression profile of pyrimidine nucleoside-metabolizing enzymes.
Yasuno H; Kurasawa M; Yanagisawa M; Sato Y; Harada N; Mori K
Oncol Rep; 2013 Feb; 29(2):451-8. PubMed ID: 23229803
[TBL] [Abstract][Full Text] [Related]
4. Long-term survival on capecitabine in two gemcitabine refractory pancreatic cancer patients. Is there a pharmacogenetic explanation?
Saif MW; Kang SP; Ledbetter L; Steg A; Diasio R; Johnson M
JOP; 2007 Nov; 8(6):799-805. PubMed ID: 17993734
[TBL] [Abstract][Full Text] [Related]
5. A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression.
Ribelles N; López-Siles J; Sánchez A; González E; Sánchez MJ; Carabantes F; Sánchez-Rovira P; Márquez A; Dueñas R; Sevilla I; Alba E
Curr Drug Metab; 2008 May; 9(4):336-43. PubMed ID: 18473752
[TBL] [Abstract][Full Text] [Related]
6. Noninvasive measurements of capecitabine metabolism in bladder tumors overexpressing thymidine phosphorylase by fluorine-19 magnetic resonance spectroscopy.
Chung YL; Troy H; Judson IR; Leek R; Leach MO; Stubbs M; Harris AL; Griffiths JR
Clin Cancer Res; 2004 Jun; 10(11):3863-70. PubMed ID: 15173095
[TBL] [Abstract][Full Text] [Related]
7. Augmentation of the antitumor activity of capecitabine by a tumor selective dihydropyrimidine dehydrogenase inhibitor, RO0094889.
Endo M; Miwa M; Eda H; Ura M; Tanimura H; Ishikawa T; Miyazaki-Nose T; Hattori K; Shimma N; Yamada-Okabe H; Ishitsuka H
Int J Cancer; 2003 Sep; 106(5):799-805. PubMed ID: 12866042
[TBL] [Abstract][Full Text] [Related]
8. Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants.
Chefrour M; Milano G; Formento P; Giacometti S; Denden A; Renée N; Iliadis A; Fischel JL; Ciccolini J
Fundam Clin Pharmacol; 2012 Aug; 26(4):530-7. PubMed ID: 21623901
[TBL] [Abstract][Full Text] [Related]
9. [Thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in soft-tissue sarcoma versus capecitabine potential].
Stepanova EV; Bokhian BIu; Petrovichev NN; Lichinitzer MR
Vopr Onkol; 2005; 51(3):314-6. PubMed ID: 16279094
[TBL] [Abstract][Full Text] [Related]
10. Contribution of thymidylate synthase to gemcitabine therapy for advanced pancreatic cancer.
Komori S; Osada S; Mori R; Matsui S; Sanada Y; Tomita H; Tokuyama Y; Takahashi T; Yamaguchi K; Yoshida K
Pancreas; 2010 Nov; 39(8):1284-92. PubMed ID: 20944490
[TBL] [Abstract][Full Text] [Related]
11. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.
Caronia D; Martin M; Sastre J; de la Torre J; García-Sáenz JA; Alonso MR; Moreno LT; Pita G; Díaz-Rubio E; Benítez J; González-Neira A
Clin Cancer Res; 2011 Apr; 17(7):2006-13. PubMed ID: 21325291
[TBL] [Abstract][Full Text] [Related]
12. Gene expression predicts differential capecitabine metabolism, impacting on both pharmacokinetics and antitumour activity.
Guichard SM; Macpherson JS; Mayer I; Reid E; Muir M; Dodds M; Alexander S; Jodrell DI
Eur J Cancer; 2008 Jan; 44(2):310-7. PubMed ID: 18077151
[TBL] [Abstract][Full Text] [Related]
13. Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study.
Garcia AA; Blessing JA; Lenz HJ; Darcy KM; Mannel RS; Miller DS; Husseinzadeh N;
Gynecol Oncol; 2005 Mar; 96(3):810-7. PubMed ID: 15721430
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacogenetics of capecitabine and its metabolites following replicate administration of two 500 mg tablet formulations.
Queckenberg C; Erlinghagen V; Baken BC; Van Os SH; Wargenau M; Kubeš V; Peroutka R; Novotný V; Fuhr U
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1081-91. PubMed ID: 26242222
[TBL] [Abstract][Full Text] [Related]
15. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.
Meropol NJ; Gold PJ; Diasio RB; Andria M; Dhami M; Godfrey T; Kovatich AJ; Lund KA; Mitchell E; Schwarting R
J Clin Oncol; 2006 Sep; 24(25):4069-77. PubMed ID: 16943524
[TBL] [Abstract][Full Text] [Related]
16. Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine.
Neff T; Blau CA
Exp Hematol; 1996 Sep; 24(11):1340-6. PubMed ID: 8862446
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.
Ouchi KF; Yanagisawa M; Sekiguchi F; Tanaka Y
Cancer Chemother Pharmacol; 2006 May; 57(5):693-702. PubMed ID: 16362295
[TBL] [Abstract][Full Text] [Related]
18. Anti-metastatic effect of capecitabine on human colon cancer xenografts in nude mouse rectum.
Ninomiya I; Terada I; Yoshizumi T; Takino T; Nagai N; Morita A; Fushida S; Nishimura G; Fujimura T; Ohta T; Miwa K
Int J Cancer; 2004 Oct; 112(1):135-42. PubMed ID: 15305385
[TBL] [Abstract][Full Text] [Related]
19. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
20. Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase.
Di Gennaro E; Piro G; Chianese MI; Franco R; Di Cintio A; Moccia T; Luciano A; de Ruggiero I; Bruzzese F; Avallone A; Arra C; Budillon A
Br J Cancer; 2010 Nov; 103(11):1680-91. PubMed ID: 21045833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
